Medicare P&T Committees Should Approve Use Of PBM Tools, BIO Says
Executive Summary
Pharmacy and therapeutics committees should be required to approve Medicare drug plans' cost containment tools, the Biotechnology Industry Organization said
You may also be interested in...
USP Final Formulary Guide Adds PPI Class, But Has Few Other Changes
Proton pump inhibitors may be the only commercially significant group of drugs to gain "pharmacologic class" status in the revisions to U.S. Pharmacopeia's model guidelines for Medicare drug plans
Medicare Rx Plans Need Six Months To Review New Drugs, Blues Say
Medicare prescription drug plans should have six months to make coverage decisions for new drugs, Blues execs are telling the Centers for Medicare & Medicaid Services
Medicare Formulary Guide Looks Beyond USP For Principles On Rx Classes
Medicare's prescription drug plan formulary review guidelines incorporate existing principles set up by outside groups rather than creating new standards